DFDS A/S
19.2.2026 07:30:00 CET | Globenewswire | Press release
DFDS ANNUAL REPORT 2025
DFDS ANNUAL REPORT 2025
| COMPANY ANNOUNCEMENT no. 05 - 19 February 2026 |
Full-year 2025
- Revenue up 4% to DKK 30.9bn
- EBIT lowered 65% to DKK 0.5bn
- Adjusted free cash flow of DKK 1.2bn
Outlook 2026
- Revenue around on level with 2025
- EBIT-range of DKK 800-1,100m
- Adjusted free cash flow above zero
| Q4 | Q4 | Change, | Full-year | Full-year | Change, | |
| DKK m | 2025 | 2024 | % | 2025 | 2024 | % |
| Revenue | 7,303 | 7,196 | 1 | 30,947 | 29,753 | 4 |
| EBITDA | 705 | 743 | - 5 | 3,743 | 4,440 | - 16 |
| EBIT | - 62 | 2 | n.a. | 520 | 1,506 | - 65 |
| Adjusted free cash flow | 440 | 164 | 168 | 1,184 | 957 | 24 |
| ROIC % | - | - | - | 1.2 | 4.4 | - |
| Financial leverage, times | - | - | - | 4.1 | 3.9 | - |
CEO’s comments
Our financial performance started to turn around in Q4 2025 as the underlying result was above 2024 adjusted for non-comparable items. We also closed the year with strong cash flow performance.
The Mediterranean ferry network turned profitable again in Q4 2025 and is expected to continue to improve profitability in 2026. The network has been adapted through capacity reductions and launch of a new pricing model.
The Nordic and Continent logistics business units also improved performance driven to a large extent by the Boost turnaround projects.
These positive developments more than offset lower results in a few other areas. There was headwind from a slowdown in Channel ferry market volumes, even though onboard spending continued to grow.
Cost coverage continued to be an issue in the quarter as competitive pressures prevented setting fully matching price increases. A cost reduction programme of DKK 300m was initiated in November 2025.
Cost reduction programme
The first phase of the cost reduction programme was completed in the last two months of 2025 when we parted ways with around 400 valued and skilled office-based colleagues. A DKK 97m redundancy cost is consequently reported in Q4 2025. During 2026, further specific cost reduction initiatives will be realised to deliver a targeted total cost reduction of DKK 300m.
Financial leverage
The outlook is expected to reduce financial leverage in 2026. The capital structure is expected to consolidate further as measured by the equity ratio and the debt/equity ratio.
The debt-to-earnings ratio, NIBD/EBITDA, is expected to decrease to below 4.0x at year-end 2026 and expected to end 2027 below 3.5x. Following this expectation, our financial leverage target, as measured by NIBD/EBITDA, is revised to a mid-term range of 2.5-3.5x from the previous long-term range of 2.0-3.0x.
Capital distribution
For 2025, the Board of Directors proposes to the annual general meeting that no capital is distributed to shareholders in order to prioritise a further deleveraging of the capital structure.
Outlook 2026
Revenue in 2026 is expected to be around level with 2025. EBIT is expected to be within a range of DKK 0.8-1.1bn. The outlook is detailed in the annual report.
Conference call today at 10.00am CET
Register ahead of the call via this link.
Access code is mailed after registration. Follow live-streaming of call via this link.
The annual report and a Q4 2025 review are attached and along with other materials also available here.
Contact
Torben Carlsen, CEO +45 33 42 32 01
Karen Boesen, CFO +45 20 58 58 40
Søren Brøndholt Nielsen, IR +45 33 42 33 59
Dennis Kjærsgaard, Media +45 42 30 38 47
About DFDS
We operate a transport network in and around Europe with an annual revenue of DKK 30bn and 16,500 full-time employees.
We move goods in trailers by ferry, road & rail, and we offer complementary and related transport and logistics solutions.
We also move car and foot passengers on short sea and overnight ferry routes.
DFDS was founded in 1866 and headquartered and listed in Copenhagen.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Attachments
- DFDS_NO_05_19_02_2026_ANNUAL_REPORT_2025
- DFDS_Q4_AND_FULL-YEAR_REVIEW
- DFDS Annual Report 2025
- DFDS-2025-12-31-en
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Orion Oyj24.10.2026 08:35:00 CEST | Press release
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
Zymeworks Inc.24.10.2026 08:30:00 CEST | Press release
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Junshi Biosciences24.10.2026 05:30:32 CEST | Press release
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
SERB Pharmaceuticals23.10.2026 21:01:27 CEST | Press release
SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026
F. Hoffmann-La Roche Ltd23.10.2026 19:30:00 CEST | Press release
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom